Deucravacitinib in psoriasis: Three-year safety and efficacy results
Another important data update presented at EADV 2023 was presented by distinguished Professor April Armstrong, Chief of Dermatology at UCLA. She unveiled groundbreaking three-year data on the safety and efficacy of deucravacitinib—a first-in-class TYK2 inhibitor. The insights not only affirm deucravacitinib’s equivalence to biological treatments in terms of efficacy, but also highlight its safety profile with no escalation in adverse events.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.